[go: up one dir, main page]

MX2017001686A - Anticuerpos anti-ceramida. - Google Patents

Anticuerpos anti-ceramida.

Info

Publication number
MX2017001686A
MX2017001686A MX2017001686A MX2017001686A MX2017001686A MX 2017001686 A MX2017001686 A MX 2017001686A MX 2017001686 A MX2017001686 A MX 2017001686A MX 2017001686 A MX2017001686 A MX 2017001686A MX 2017001686 A MX2017001686 A MX 2017001686A
Authority
MX
Mexico
Prior art keywords
antibodies
ceramide
ceramide antibodies
apoptosis
humanized
Prior art date
Application number
MX2017001686A
Other languages
English (en)
Other versions
MX391141B (es
Inventor
Rotolo Jimmy
Kolesnick Richard
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2017001686A publication Critical patent/MX2017001686A/es
Publication of MX391141B publication Critical patent/MX391141B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen anticuerpos monoclonales dirigidos a ceramidas que inhiben la apoptosis. También se describen las versiones humanizadas y del scFv de los anticuerpos. Se describen los métodos para la prevención o tratamiento de la apoptosis en un sujeto mediante la administración de los anticuerpos anti-ceramida.
MX2017001686A 2014-08-07 2015-08-07 Anticuerpos anti-ceramida. MX391141B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462034453P 2014-08-07 2014-08-07
PCT/US2015/044144 WO2016022883A1 (en) 2014-08-07 2015-08-07 Anti-ceramide antibodies

Publications (2)

Publication Number Publication Date
MX2017001686A true MX2017001686A (es) 2017-09-01
MX391141B MX391141B (es) 2025-03-21

Family

ID=55264608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001686A MX391141B (es) 2014-08-07 2015-08-07 Anticuerpos anti-ceramida.

Country Status (12)

Country Link
US (4) US10450385B2 (es)
EP (2) EP3177650B1 (es)
JP (1) JP6670297B2 (es)
KR (1) KR102296416B1 (es)
CN (1) CN107074949B (es)
AU (1) AU2015300902B2 (es)
CA (1) CA2957415C (es)
IL (1) IL250374B (es)
MX (1) MX391141B (es)
RU (1) RU2717651C2 (es)
SG (1) SG11201700787XA (es)
WO (1) WO2016022883A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
CA3048224A1 (en) 2016-12-23 2018-06-28 Bluefin Biomedicine, Inc. Anti-sez6l2 antibodies and antibody drug conjugates
WO2020231629A1 (en) 2019-05-16 2020-11-19 Snake River Bioscience, Inc. Compositions and methods for the treatment of major depressive disorder
JP7623706B2 (ja) * 2019-06-06 2025-01-29 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド Ｃｄ７３に特異的な結合分子と結合分子の使用
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
KR102245082B1 (ko) * 2020-02-14 2021-04-26 단국대학교 천안캠퍼스 산학협력단 치주인대전구세포 표면에 특이적으로 결합하는 두 가지 IgG 타입 단일클론항체 LG43, LG73 및 그의 용도
IL296550A (en) 2020-03-18 2022-11-01 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
CN117320750A (zh) * 2021-03-16 2023-12-29 纪念斯隆-凯特琳癌症中心 用抗神经酰胺抗体增强伤口愈合
WO2024226646A2 (en) * 2023-04-25 2024-10-31 Memorial Sloan-Kettering Cancer Center Dlk1 -targeting antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPH02128697A (ja) * 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
US7897753B2 (en) * 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
RU2310393C1 (ru) * 2006-02-16 2007-11-20 ФГУ Научно-исследовательский институт по изучению лепры Федерального агентства по здравоохранению и социальному развитию Российской Федерации Способ прогнозирования обострений лепрозных невропатий у больных лепрой
CA2686722C (en) * 2007-05-06 2017-08-15 Sloan-Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US8410251B2 (en) * 2008-06-20 2013-04-02 National University Corporation Okayama University Antibody against calcified globule and use of the same
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
ES2641612T3 (es) * 2009-04-17 2017-11-10 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos
FR2971250A1 (fr) * 2011-02-07 2012-08-10 Univ Nantes Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
KR101256351B1 (ko) 2011-11-22 2013-04-19 김석진 필터 삽입공을 갖는 카메라 후드
DK2818483T3 (en) * 2012-02-21 2017-10-23 Toray Industries Medical composition for the treatment and / or prevention of cancer
JP6257600B2 (ja) * 2012-05-25 2018-01-10 スローン ケタリング インスティテュート フォア キャンサー リサーチ Ｇｉ症候群及び移植片対宿主病の治療方法
IL296550A (en) * 2020-03-18 2022-11-01 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies

Also Published As

Publication number Publication date
US20230416409A1 (en) 2023-12-28
CN107074949A (zh) 2017-08-18
SG11201700787XA (en) 2017-02-27
US20250197524A1 (en) 2025-06-19
RU2017105596A3 (es) 2019-04-17
WO2016022883A1 (en) 2016-02-11
CN107074949B (zh) 2021-06-15
RU2717651C2 (ru) 2020-03-24
US10450385B2 (en) 2019-10-22
IL250374B (en) 2021-04-29
AU2015300902B2 (en) 2020-05-28
CA2957415C (en) 2021-07-13
MX391141B (es) 2025-03-21
US20190389970A1 (en) 2019-12-26
KR102296416B1 (ko) 2021-09-01
US11447572B2 (en) 2022-09-20
JP2017527544A (ja) 2017-09-21
JP6670297B2 (ja) 2020-03-18
AU2015300902A1 (en) 2017-03-02
EP3177650B1 (en) 2025-11-05
US20170335014A1 (en) 2017-11-23
EP3177650A4 (en) 2018-01-03
BR112017002433A2 (pt) 2017-11-28
NZ728981A (en) 2024-03-22
EP3177650A1 (en) 2017-06-14
KR20170066327A (ko) 2017-06-14
RU2017105596A (ru) 2018-09-07
CA2957415A1 (en) 2016-02-11
EP4681733A2 (en) 2026-01-21
IL250374A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MX2017001686A (es) Anticuerpos anti-ceramida.
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
GEAP202114453A (en) Anti-lag3 antibodies and antigen-binding fragments
IL259924A (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2016001871A1 (es) Anticuerpos humanos para pd-1
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
MX388181B (es) Anticuerpos anti-pd-1.
HUE050831T2 (hu) Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával
GEAP202114450A (en) Anti-tigit antibodies
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
CL2016001979A1 (es) Métodos de tratamiento de enfermedad de alzheimer.
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
SI3390450T1 (sl) Humanizirana protitelesa proti CD-28, formulirana za dajanje ljudem